Stockreport

Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Contineum Therapeutics, Inc. - Common stock  (CTNM) 
PDF -Enrollment for PIPE-307 VISTA trial on track--Strong cash position of $214 million at the end of Q3 expected to support operations through 2027--Multiple potential clin [Read more]